See at a glance what Vernalis has in development
See the status of all programmes, both partnered and un-partnered.
Explore NCE Pipeline
We have two programmes in CNS both focussed on pain management
Central Nervous System
We have six programmes in Oncology
Four partnered and two available for out-licensing
We have a single programme focussed on inflammation which is partnered
Vernalis plc ("Vernalis" or the "Company") provides an update ahead of its Annual General Meeting ("AGM") being held today at 10.30 am at the offices of Covington & Burling, 265 Strand, London WC2R 1BH.
More information on Vernalis and its pipeline ...
Company fact sheet
Explore the pipeline ...
T: 0118 938 0000 F: 0118 938 0001Contact informationMaps and directionsContact form
To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and firstname.lastname@example.org or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch